The US Food and Drug Administration (FDA) has approved dihydroergotamine (DHE) nasal powder (Atzumi, Satsuma Pharmaceuticals Inc) for the acute treatment of migraine with or without aura in adults ...

New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA ... more about this approval in Johnson & Johnson’s news ...

Shares in Axsome Therapeutics have rocketed on FDA approval ... to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice a week ...

Health care giantJohnson & Johnson said on Wednesday the US Food and Drug Administration (FDA) has approved its drug to treat patients aged 12 years and older with an immune-mediated disorder.

Oral migraine treatments include Axsome Therapeutics' recently approved Symbravo and Pfizer's Nurtec ODT. Pfizer also sells a nasal spray ... it said. The FDA had previously declined to approve ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

(RTTNews) - Johnson & Johnson (JNJ) announced the FDA has approved IMAAVY, a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis. The approval is supported ...

New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVY ... Learn more about this approval in Johnson ...

New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVY ... Learn more about this approval in Johnson ...